Elicio Therapeutics, Inc. (ELTX)
(Delayed Data from NSDQ)
$9.20 USD
+0.13 (1.43%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $9.19 -0.01 (-0.11%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELTX 9.20 +0.13(1.43%)
Will ELTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELTX
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
ELTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
Other News for ELTX
Elicio Therapeutics GAAP EPS of -$0.66
JonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX)
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate ...
Elicio Therapeutics (ELTX) Advances with Positive Interim Trial Review
Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2